Thursday, 6 November 2014
Immune booster combined with checkpoint blocker improves survival in metastatic melanoma
Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Patients in the clinical trial who got the combined therapies also had fewer serious adverse side effects than those who received only ipilimumab. Read more here.
Subscribe to:
Post Comments (Atom)
Interesting post. I have been wondering about this issue, so thanks for posting. Pretty cool post. It’s really very nice and Useful post. Thanks
ReplyDeleteimmune boosters for adults
This is such a great resource that you are providing and you give it away for free. I love seeing blog that understand the value of providing a quality resource for free.
ReplyDeletebest health teas